Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE1
Clinical Trials Related to Trastuzumab
Related studies linked through entity extraction aliases.
Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling
- Status
- UNKNOWN
- Phase
- PHASE2
Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Concurrent Neoadjuvant Chemoradiotherapy Plus Trastuzumab in the Treatment of Siewert II ，III of Human Epidermal Growth Factor Receptor-2(HER-2) Positive Gastroesophageal Junction Adenocarcinoma： A Randomized, Controlled Clinical Study
- Status
- UNKNOWN
- Phase
- PHASE2
12 weekS Adjuvant dOcetaxel Plus trastuzumaB in Patients With Small, Node-negative, HER2-positive Breast cancER (SOBER)
- Status
- UNKNOWN
- Phase
- PHASE2
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
- Status
- COMPLETED
- Phase
- PHASE2
4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE2
MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.
- Status
- COMPLETED
- Phase
- PHASE2
FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab
- Status
- COMPLETED
- Phase
- PHASE3
Efficacy and Safety of Precision Therapy in Refractory Tumor
- Status
- UNKNOWN
- Phase
- PHASE2
Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE3
Investigating Cardiovascular Adverse Events Related to Cancer Treatment
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- N/A
TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2